NCT04600219

Brief Summary

The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the dialysis prognosis in chronic hemodialysis patients

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2018

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

October 21, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 23, 2020

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

November 3, 2020

Status Verified

November 1, 2020

Enrollment Period

3.9 years

First QC Date

October 21, 2020

Last Update Submit

November 1, 2020

Conditions

Hemodialysis Complication

Keywords

hemodialysisAxlprognosis

Outcome Measures

Primary Outcomes (2)

  • death

    death

    3 years

  • dialysis complication

    vascular access failure, stroke, acute coronary syndrome, heart failure

    3 years

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

End-stage renal disease patients undergoing hemodialysis treatment

You may qualify if:

  • hemodialysis for more than 6 months

You may not qualify if:

  • patients who received warfarin therapy;
  • patients with chronic infectious disease or acute infection;
  • patients with hemodialysis inadequacy;
  • the age of patients is older than 65 years or younger than 18 years.
  • patients who can not sign an informed consent or disagree to follow up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, 200272, China

Location

Study Officials

  • Ai Peng, MD,PhD

    Shanghai 10th People's Hospital

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of the department of Nephrology,Shanghai 10th people's hospital

Study Record Dates

First Submitted

October 21, 2020

First Posted

October 23, 2020

Study Start

January 1, 2018

Primary Completion

December 1, 2021

Study Completion

December 1, 2021

Last Updated

November 3, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)